Sign inCreate account

Report workspace tools

NCT04610476UNKNOWNanonymous

A Prospective, Randomized, Controlled, Open Label, Assessor-blinded, Parallel-group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy in a Treat-to-target Approach on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Sponsor

Source record

University of Erlangen-Nürnberg Medical School

Phase

Source record

PHASE3

Modality

AI-normalized

small molecule

Target

AI-normalized

Prednisolone, Sulfasalazine, Leflunomide, Methotrexate, Tofacitinib, Apremilast, Etanercept, Adalimumab, Infliximab, Certolizumab pegol, Golimumab, Abatacept, Secukinumab, Ixekizumab, Ustekinumab

Indication / condition

AI-normalized

Psoriatic Arthritis

Intervention

Source record

Prednisolone, Sulfasalazine, Leflunomide, Methotrexate, Tofacitinib, Apremilast, Etanercept, Adalimumab, Infliximab, Certolizumab pegol, Golimumab, Abatacept, Secukinumab, Ixekizumab, Ustekinumab

Source & freshness

Source record

NCT ID

NCT04610476

Original source

ClinicalTrials.gov

Source last updated

Nov 14, 2022

Ingested at

Jun 11, 2026

Internal sync

Jun 11, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT04610476

Title

A Prospective, Randomized, Controlled, Open Label, Assessor-blinded, Parallel-group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy in a Treat-to-target Approach on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Sponsor

University of Erlangen-Nürnberg Medical School

Status

UNKNOWN

Phase

PHASE3

Condition raw

Psoriatic Arthritis, Withdrawal, Reduction

Condition normalized

Psoriatic Arthritis, Withdrawal, Reduction

Modality raw

small molecule

Modality normalized

small molecule

Target raw

Prednisolone, Sulfasalazine, Leflunomide, Methotrexate, Tofacitinib, Apremilast, Etanercept, Adalimumab, Infliximab, Certolizumab pegol, Golimumab, Abatacept, Secukinumab, Ixekizumab, Ustekinumab

Target normalized

Prednisolone, Sulfasalazine, Leflunomide, Methotrexate, Tofacitinib, Apremilast, Etanercept, Adalimumab, Infliximab, Certolizumab pegol, Golimumab, Abatacept, Secukinumab, Ixekizumab, Ustekinumab

Interventions

Prednisolone, Sulfasalazine, Leflunomide, Methotrexate, Tofacitinib, Apremilast, Etanercept, Adalimumab, Infliximab, Certolizumab pegol, Golimumab, Abatacept, Secukinumab, Ixekizumab, Ustekinumab

Public preview

Source record

The rationale for this study is to investigate whether in psoriatic arthritis (PsA) patients in stable remission a reduction or complete discontinuation of immunosuppressive therapy can be achieved in a treat-to-target approach while maintaining in remission. Due to the lack of reliable data that answers the question of how to safely reduce medication in which patients, this study will test a pragmatic treatment algorithm that can be applied in clinical practice and that offers a gradual reduction with escape strategies in order to facilitate the maintenance of remission.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Prospective, Randomized, Controlled, Open Label, Assessor-blinded, Parallel-group Phase III Clinical Trial to Evaluate the Impact of Tapering Systemic Immunosuppressive Therapy in a Treat-to-target Approach on Maintaining Minimal Disease Activity in Adult Subjects With Psoriatic Arthritis

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT04610476

Status

UNKNOWN

Phase

PHASE3

Sponsor

University of Erlangen-Nürnberg Medical School

Executive brief

Investment-Ready Snapshot

The rationale for this study is to investigate whether in psoriatic arthritis (PsA) patients in stable remission a reduction or complete discontinuation of immunosuppressive therapy can be achieved in a treat-to-target approach while maintaining in remission. Due to the lack of reliable data that answers the question of how to safely reduce medication in which patients, this study will test a pragmatic treatment algorithm that can be applied in clinical practice and that offers a gradual reduction with escape strategies in order to facilitate the maintenance of remission.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedNov 14, 2022
Internal syncJun 11, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT04610476

Indication

Psoriatic Arthritis

Modality

small molecule

Target

Prednisolone, Sulfasalazine, Leflunomide, Methotrexate, Tofacitinib, Apremilast, Etanercept, Adalimumab, Infliximab, Certolizumab pegol, Golimumab, Abatacept, Secukinumab, Ixekizumab, Ustekinumab

Intervention

Prednisolone, Sulfasalazine, Leflunomide, Methotrexate, Tofacitinib, Apremilast, Etanercept, Adalimumab, Infliximab, Certolizumab pegol, Golimumab, Abatacept, Secukinumab, Ixekizumab, Ustekinumab

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.